Last reviewed · How we verify
NgG HTD investigational vaccine — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
NgG HTD investigational vaccine (NgG HTD investigational vaccine) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| NgG HTD investigational vaccine TARGET | NgG HTD investigational vaccine | GlaxoSmithKline | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- NgG HTD investigational vaccine CI watch — RSS
- NgG HTD investigational vaccine CI watch — Atom
- NgG HTD investigational vaccine CI watch — JSON
- NgG HTD investigational vaccine alone — RSS
Cite this brief
Drug Landscape (2026). NgG HTD investigational vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/ngg-htd-investigational-vaccine. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab